<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34828592</PMID><DateRevised><Year>2024</Year><Month>04</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2227-9032</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>11</Issue><PubDate><Year>2021</Year><Month>Nov</Month><Day>12</Day></PubDate></JournalIssue><Title>Healthcare (Basel, Switzerland)</Title><ISOAbbreviation>Healthcare (Basel)</ISOAbbreviation></Journal><ArticleTitle>Back to the Future? Immunoglobulin Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1546</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/healthcare9111546</ELocationID><Abstract><AbstractText>The findings of controlled trials on use of intravenous immunoglobulin G (IV IgG) to treat myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) are generally viewed as representing mixed results. On detailed review, a clearer picture emerges, which suggests that the potential therapeutic value of this intervention has been underestimated. Our analysis is consistent with the propositions that: (1) IgG is highly effective for a proportion of patients with severe and well-characterised ME/CFS; (2) responders can be predicted with a high degree of accuracy based on markers of immune dysfunction. Rigorous steps were taken in the research trials to record adverse events, with transient symptom exacerbation commonly experienced in both intervention and placebo control groups, suggesting that this reflected the impact of participation on people with an illness characterised by post-exertional symptom exacerbation. Worsening of certain specific symptoms, notably headache, did occur more commonly with IgG and may have been concomitant to effective treatment, being associated with clinical improvement. The findings emerging from this review are supported by clinical observations relating to treatment of patients with severe and very severe ME/CFS, for whom intramuscular and subcutaneous administration provide alternative options. We conclude that: (1) there is a strong case for this area of research to be revived; (2) pending further research, clinicians would be justified in offering a course of IgG to selected ME/CFS patients at the more severe end of the spectrum. As the majority of trial participants had experienced an acute viral or viral-like onset, we further suggest that IgG treatment may be pertinent to the care of some patients who remain ill following infection with SARS-CoV-2 virus.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brownlie</LastName><ForeName>Helen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Independent Researcher and Former Local Government Officer, Social Policy and Research, Glasgow G2 4P, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Speight</LastName><ForeName>Nigel</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Paediatrician and Independent Researcher, Durham DH1 1QN, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Healthcare (Basel)</MedlineTA><NlmUniqueID>101666525</NlmUniqueID><ISSNLinking>2227-9032</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cell-mediated immunity</Keyword><Keyword MajorTopicYN="N">chronic fatigue syndrome</Keyword><Keyword MajorTopicYN="N">immunoglobulin</Keyword><Keyword MajorTopicYN="N">long-COVID</Keyword><Keyword MajorTopicYN="N">myalgic encephalomyelitis</Keyword><Keyword MajorTopicYN="N">post-acute sequelae of COVID-19</Keyword><Keyword MajorTopicYN="N">viral onset</Keyword></KeywordList><CoiStatement>The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>27</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34828592</ArticleId><ArticleId IdType="pmc">PMC8623195</ArticleId><ArticleId IdType="doi">10.3390/healthcare9111546</ArticleId><ArticleId IdType="pii">healthcare9111546</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lloyd A., Wakefield D., Broughton C., Dwyer J. Immunological abnormalities in the chronic fatigue syndrome. Med. J. Aust. 1989;151:122&#x2013;124. doi: 10.5694/j.1326-5377.1989.tb139594.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.5694/j.1326-5377.1989.tb139594.x</ArticleId><ArticleId IdType="pubmed">2787888</ArticleId></ArticleIdList></Reference><Reference><Citation>Behan P., Behan W., Bell E. The postviral fatigue syndrome&#x2014;An analysis of the findings in 50 cases. J. Infect. 1985;10:211&#x2013;212. doi: 10.1016/S0163-4453(85)92488-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0163-4453(85)92488-0</ArticleId><ArticleId IdType="pubmed">2993423</ArticleId></ArticleIdList></Reference><Reference><Citation>Caligiuri M., Murray C., Buchwald D., Levine H., Cheney P., Peterson D., Komaroff A.L., Ritz J. Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. J. Immunol. 1987;139:3306&#x2013;3313.</Citation><ArticleIdList><ArticleId IdType="pubmed">2824604</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosato G., Straus S., Henle W., Pike S.E., Blease R.M. Characteristic T cell dysfunction in patients with chronic Epstein-Barr virus infection (chronic mononucleosis syndrome) J. Immunol. 1985;134:3082&#x2013;3088.</Citation><ArticleIdList><ArticleId IdType="pubmed">2984282</ArticleId></ArticleIdList></Reference><Reference><Citation>Kibler R., Lucas D.O., Hicks M.H., Poulos B.T., Jones J.F. Immune function in chronic Epstein-Barr virus infection. J. Clin. Immunol. 1985;5:46&#x2013;54. doi: 10.1007/BF00915168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00915168</ArticleId><ArticleId IdType="pubmed">2579970</ArticleId></ArticleIdList></Reference><Reference><Citation>Borysiewicz L.K., Haworth S.J., Cohen J., Mundin J., Rickinson A., Sissons J.G.P. Epstein-Barr virus-specific immune defects in patients with persistent symptoms following infectious mononucleosis. QJM Int. J. Med. 1986;58:111&#x2013;121. doi: 10.1093/oxfordjournals.qjmed.a067944.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.qjmed.a067944</ArticleId><ArticleId IdType="pubmed">3012622</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdoch J.C. Cell mediated immunity in patients with myalgic encephalomyelitis syndrome. N. Z. Med. J. 1988;101:511&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">3261407</ArticleId></ArticleIdList></Reference><Reference><Citation>Subira M.L., Castilla A., Civeira M.-P., Prieto J. Deficient display of CD3 on lymphocytes of patients with chronic fatigue syndrome. J. Infect. Dis. 1989;160:165&#x2013;166. doi: 10.1093/infdis/160.1.165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/160.1.165</ArticleId><ArticleId IdType="pubmed">2525153</ArticleId></ArticleIdList></Reference><Reference><Citation>Prieto J., Subira M.L., Castilla A., Serrano M. Naloxone-reversible monocyte dysfunction in patients with chronic fatigue syndrome. Scand. J. Immunol. 1989;30:13&#x2013;20. doi: 10.1111/j.1365-3083.1989.tb01183.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-3083.1989.tb01183.x</ArticleId><ArticleId IdType="pubmed">2526966</ArticleId></ArticleIdList></Reference><Reference><Citation>Read P., Spickett G., Harvey J., Edwards A.J., Larson H.E. IgG1 subclass deficiency in patients with chronic fatigue syndrome. Lancet. 1988;1:241&#x2013;242. doi: 10.1016/S0140-6736(88)91091-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(88)91091-4</ArticleId><ArticleId IdType="pubmed">2893063</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff A.L., Geiger A.M., Wormsley S. IgG subclass deficiencies in the chronic fatigue syndrome. Lancet. 1988;1:288&#x2013;289. doi: 10.1016/S0140-6736(88)92109-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(88)92109-5</ArticleId><ArticleId IdType="pubmed">2897551</ArticleId></ArticleIdList></Reference><Reference><Citation>Linde A., Hammearstrom L., Smith C. IgG subclass deficiency and chronic fatigue syndrome. Lancet. 1988;1:885&#x2013;886. doi: 10.1016/S0140-6736(88)91633-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(88)91633-9</ArticleId><ArticleId IdType="pubmed">2895392</ArticleId></ArticleIdList></Reference><Reference><Citation>Lloyd A., Hickie I., Wakefield D., Boughton C., Dwyer A. A double-blind placebo controlled trial of intravenous immunoglobulin therapy in patients with chronic fatigue syndrome. Am. J. Med. 1990;89:561&#x2013;568. doi: 10.1016/0002-9343(90)90173-B.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-9343(90)90173-B</ArticleId><ArticleId IdType="pubmed">2146875</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson P.K., Shepard J., Macres M., Schenck C., Crosson J., Rechtman D., Lurie N. A controlled trial of intravenous immunoglobulin G in chronic fatigue syndrome. Am. J. Med. 1990;89:554&#x2013;560. doi: 10.1016/0002-9343(90)90172-A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-9343(90)90172-A</ArticleId><ArticleId IdType="pubmed">2239975</ArticleId></ArticleIdList></Reference><Reference><Citation>Archard L., Bowles N., Behan P., Bell E., Doyle D. Postviral fatigue syndrome: Persistence of enterovirus RNA in muscle and elevated creatine kinase. J. R. Soc. Med. 1988;81:326&#x2013;329. doi: 10.1177/014107688808100608.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/014107688808100608</ArticleId><ArticleId IdType="pmc">PMC1291623</ArticleId><ArticleId IdType="pubmed">3404526</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousef G., Mann G., Smith D., Bell E., Murugesan V., Mccartney R., Mowbray J. Chronic enterovirus infection in patients with postviral fatigue syndrome. Lancet. 1988;1:146&#x2013;150. doi: 10.1016/S0140-6736(88)92722-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(88)92722-5</ArticleId><ArticleId IdType="pubmed">2892990</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakefield D., Lloyd A. Pathophysiology of myalgic encephalomyelitis. Lancet. 1987;2:918&#x2013;919. doi: 10.1016/S0140-6736(87)91408-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(87)91408-5</ArticleId><ArticleId IdType="pubmed">2889115</ArticleId></ArticleIdList></Reference><Reference><Citation>Strauss S.E. Intravenous immunoglobulin treatment for the chronic fatigue syndrome. Am. J. Med. 1990;89:551&#x2013;552. doi: 10.1016/0002-9343(90)90171-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-9343(90)90171-9</ArticleId><ArticleId IdType="pubmed">2239974</ArticleId></ArticleIdList></Reference><Reference><Citation>Dwyer J. Intravenous therapy with gammaglobulin. Adv. Intern. Med. 1987;32:111&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">3548246</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelfand E. The use of intravenous immune globulin in collagen vascular disorders: A potentially new modality of therapy. J. Allergy Clin. Immunol. 1989;84:613&#x2013;616. doi: 10.1016/0091-6749(89)90199-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0091-6749(89)90199-1</ArticleId><ArticleId IdType="pubmed">2794302</ArticleId></ArticleIdList></Reference><Reference><Citation>DuBois R.E. Gamma globulin therapy for chronic mononucleosis syndrome. AIDS Res. 1986;2((Suppl. S1)):S191&#x2013;S195.</Citation><ArticleIdList><ArticleId IdType="pubmed">2435296</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe K.S. Double-blind randomized controlled trial to assess the efficacy of intravenous gammaglobulin for the management of chronic fatigue syndrome in adolescents. J. Psychiatr. Res. 1997;31:133&#x2013;147. doi: 10.1016/S0022-3956(96)00047-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-3956(96)00047-7</ArticleId><ArticleId IdType="pubmed">9201655</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe K.S. Five-year follow-up of young people with chronic fatigue syndrome following the double blind randomised controlled intravenous gammaglobulin trial. J. Chronic Fatigue Syndr. 1999;5:97&#x2013;107. doi: 10.1300/J092v05n03_08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1300/J092v05n03_08</ArticleId></ArticleIdList></Reference><Reference><Citation>Vollmer-Conna U., Hickie I., Hadzi-Pavlovic D., Tymms K., Wakefield D., Dwyer J., Lloyd A. Intravenous immunoglobulin is ineffective in the treatment of patients with chronic fatigue syndrome. Am. J. Med. 1997;103:38&#x2013;43. doi: 10.1016/S0002-9343(97)90045-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9343(97)90045-0</ArticleId><ArticleId IdType="pubmed">9236484</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull N., Shaw E.J., Baker R., Dunsdon S., Costin N., Britton G., Kuntze S., Norman R. Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (or Encephalopathy): Diagnosis and Management of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (or Encephalopathy) in Adults and Children. National Institute for Clinical Excellence Clinical Guideline 53. The Royal College of General Practitioners and the National Collaborating Centre for Primary Care; London, UK: 2007.</Citation></Reference><Reference><Citation>Department of Health . A Report of the CFS/ME Working Group: Report to the Chief Medical Officer of an Independent Working Group; Annex 5&#x2014;Management of CFS/ME&#x2014;Evidence Base. Department of Health; London, UK: 2002.</Citation></Reference><Reference><Citation>Hartwig J., Sotzny F., Bauer S., Heidecke H., Riemekasten G., Dragun D., Meisel C., Dames C., Grabowski P., Scheibenbogen C. IgG Stimulated &#x392;2 adrenergic receptor activation is attenuated in patients with ME/CFS. Brain Behav. Immun. Health. 2020;3:100047. doi: 10.1016/j.bbih.2020.100047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbih.2020.100047</ArticleId><ArticleId IdType="pmc">PMC8474590</ArticleId><ArticleId IdType="pubmed">34589837</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucker M.E. Small-Fiber Polyneuropathy May Underlie Dysautonomia in ME/CFS (Report Following IACFS Conference Presentation by Ryan Wheelan)  [(accessed on 14 August 2021)];Medscape. 2020  Available online:  https://www.medscape.com/viewarticle/936745.</Citation></Reference><Reference><Citation>Wakiro S., Ono H., Matsutani T., Nakamura M., Shin I., Amano K., Suzuki R., Tamamura T. Skewing of the B cell receptor repertoire in myalgic encephalomyelitis/chronic fatigue syndrome. Brain Behav. Immun. 2021;95:245&#x2013;255. doi: 10.1016/j.bbi.2021.03.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.03.023</ArticleId><ArticleId IdType="pubmed">33794313</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallings R., Dalziel S. International Association of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (IACFS/ME) Conference Report 2020.  [(accessed on 29 June 2021)].  Available online:  https://www.iacfsme.org/2020-conference-summaries/</Citation></Reference><Reference><Citation>US ME/CFS Clinician Coalition  Treatment Recommendations (Read More) 2021.  [(accessed on 7 July 2021)].  Available online:  </Citation></Reference><Reference><Citation>Bateman L., Bested A.C., Bonilla H.F., Chheda B.V., Chu L., Curtin J.M., Dempsey T.T., Dimmock M.E., Dowell T.G., Felsenstein D., et al. Myalgic Encephalomyelitis / Chronic Fatigue Syndrome: Essentials of Diagnosis and Management. Mayo Clin. Proc. 2021:S0025619621005139. doi: 10.1016/j.mayocp.2021.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2021.07.004</ArticleId><ArticleId IdType="pubmed">34454716</ArticleId></ArticleIdList></Reference><Reference><Citation>UK Government  Ban Lifted to Allow UK Blood Plasma to be Used for Life-Saving Treatments Press Release 25 February 2021.  [(accessed on 7 July 2021)]; Available online:  https://www.gov.uk/government/news/ban-lifted-to-allow-uk-blood-plasma-to-be-used-for-life-saving-treatments.</Citation></Reference><Reference><Citation>Garc&#xed;a-Abell&#xe1;n J., Padilla S., Fern&#xe1;ndez-Gonz&#xe1;lez M., Garc&#xed;a J.A., Agull&#xf3; V., Andreo M., Ruiz S., Galiana A., Guti&#xe9;rrez F., Masi&#xe1; M. Antibody response to SARS-CoV-2 is associated with long-term clinical outcome in patients with COVID-19: A longitudinal study. J. Clin. Immunol. 2021;41:1490&#x2013;1501. doi: 10.1007/s10875-021-01083-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-021-01083-7</ArticleId><ArticleId IdType="pmc">PMC8285689</ArticleId><ArticleId IdType="pubmed">34273064</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C., Darley D., Howe A., Munier C.M.L., Patel S.K., Juno J.A., Burrell L.M., Kent S.J., Dore G.J., Kelleher A.D., et al. Immunological dysfunction persists for 8 months following initial mild-moderate SARS-CoV-2 infection. MedRVix. 2021 doi: 10.1101/2021.06.01.21257759.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.01.21257759</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes G.P., Kaplan J.E., Gantz N.M., Komaroff A.L., Schonberger L.B., Straus S.E., Jones J.F., DuBois R.E., Brus I., Tosayo G., et al. Chronic fatigue syndrome: A working case definition. Ann. Intern. Med. 1988;108:387&#x2013;389. doi: 10.7326/0003-4819-108-3-387.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-108-3-387</ArticleId><ArticleId IdType="pubmed">2829679</ArticleId></ArticleIdList></Reference><Reference><Citation>Lloyd A.R., Hickie I., Boughton C.R., Wakefield D., Spencer O. Prevalence of chronic fatigue syndrome in an Australian population. Med. J. Aust. 1990;153:522&#x2013;528. doi: 10.5694/j.1326-5377.1990.tb126191.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.5694/j.1326-5377.1990.tb126191.x</ArticleId><ArticleId IdType="pubmed">2233474</ArticleId></ArticleIdList></Reference><Reference><Citation>Schluederberg A., Straus S.E., Peterson P., Blumenthal S., Komaroff A.L., Spring S.B., Landay A., Buchwald D. Chronic fatigue syndrome research: Definition and medical outcome assessment. Ann. Intern. Med. 1992;117:325. doi: 10.7326/0003-4819-117-4-325.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-117-4-325</ArticleId><ArticleId IdType="pubmed">1322076</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuda K., Straus S., Hickie I., Sharpe M., Dobbins J., Komaroff A., The International CFS Study Group The chronic fatigue syndrome: A comprehensive approach to its definition and study. Ann. Intern. Med. 1994;121:953&#x2013;959. doi: 10.7326/0003-4819-121-12-199412150-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-121-12-199412150-00009</ArticleId><ArticleId IdType="pubmed">7978722</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry. 1960;23:56&#x2013;62. doi: 10.1136/jnnp.23.1.56.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.23.1.56</ArticleId><ArticleId IdType="pmc">PMC495331</ArticleId><ArticleId IdType="pubmed">14399272</ArticleId></ArticleIdList></Reference><Reference><Citation>Zung W.W.K. A self-rating depression scale. Arch. Gen. Psychiatry. 1965;12:63. doi: 10.1001/archpsyc.1965.01720310065008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpsyc.1965.01720310065008</ArticleId><ArticleId IdType="pubmed">14221692</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart A.L., Hays R.D., Ware J.E. The MOS short-form general health survey: Reliability and validity in a patient population. Med. Care. 1988;26:724&#x2013;735. doi: 10.1097/00005650-198807000-00007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005650-198807000-00007</ArticleId><ArticleId IdType="pubmed">3393032</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart A.L. Functional status and well-being of patients with chronic conditions: Results from the medical outcomes study. JAMA. 1989;262:907. doi: 10.1001/jama.1989.03430070055030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1989.03430070055030</ArticleId><ArticleId IdType="pubmed">2754790</ArticleId></ArticleIdList></Reference><Reference><Citation>Spielberger C.D. Self-Evaluation Questionnaire State Trait Anxiety Inventory. Consulting Psychologists Press; Paolo Alto, CA, USA: 1977.</Citation></Reference><Reference><Citation>Beck A.T. An inventory for measuring depression. Arch. Gen. Psychiatry. 1961;4:561. doi: 10.1001/archpsyc.1961.01710120031004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpsyc.1961.01710120031004</ArticleId><ArticleId IdType="pubmed">13688369</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg D.P., Williams P. A User&#x2019;s Guide to the General Health Questionnaire. Reprint. GL Assessment; London, UK: 2006.</Citation></Reference><Reference><Citation>Achenbach T.M., Edelbrock C.S. Manual for the Child Behavior Checklist and Revised Child Behavior Profile. Univ Vermont/Dept Psychiatry; Burlington, VT, USA: 1983.</Citation></Reference><Reference><Citation>Karnofsky D., Abelmann W., Craver L., Burchenal J. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer. 1948;1:634&#x2013;656. doi: 10.1002/1097-0142(194811)1:4&lt;634::AID-CNCR2820010410&gt;3.0.CO;2-L.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1097-0142(194811)1:4&lt;634::AID-CNCR2820010410&gt;3.0.CO;2-L</ArticleId></ArticleIdList></Reference><Reference><Citation>McNair D.M., Lorr M., Droppleman L.F. Profile of Mood States: Manual. Educational and Industrial Testing Service; San Diego, CA, USA: 1981.</Citation></Reference><Reference><Citation>Gill W.M. Monitoring the subjective well-being of chronically Ill patients over time. Commun. Health Stud. 2010;8:288&#x2013;296. doi: 10.1111/j.1753-6405.1984.tb00456.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1753-6405.1984.tb00456.x</ArticleId><ArticleId IdType="pubmed">6518747</ArticleId></ArticleIdList></Reference><Reference><Citation>Lloyd A.R., Wakefield D., Boughton C., Dwyer J. What is myalgic encephalomyelitis? Lancet. 1988;331:1286&#x2013;1287. doi: 10.1016/S0140-6736(88)92107-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(88)92107-1</ArticleId><ArticleId IdType="pubmed">2897549</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson P.K., Schenck C.H., Sherman R. Chronic fatigue syndrome in Minnesota. Minn. Med. 1991;74:21&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">1861659</ArticleId></ArticleIdList></Reference><Reference><Citation>Corriel R.N., Kniker W.I., McBryde J.L., Lesourd B.M. Cell-mediated immunity in schoolchildren assessed by multitest skin testing: Normal values and proposed scoring system for healthy children. Am. J. Dis. Child. 1985;139:141. doi: 10.1001/archpedi.1985.02140040039022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpedi.1985.02140040039022</ArticleId><ArticleId IdType="pubmed">3976586</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns R., Hotopf M. A Systematic review describing the prognosis of chronic fatigue syndrome. Occup. Med. 2005;55:20&#x2013;31. doi: 10.1093/occmed/kqi013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/occmed/kqi013</ArticleId><ArticleId IdType="pubmed">15699087</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerr J.R., Cunniffe V.S., Kelleher P., Bernstein R.M., Bruce I.N. Successful intravenous immunoglobulin therapy in 3 cases of parvovirus B19&#x2014;Associated chronic fatigue syndrome. Clin. Infect. Dis. 2003;36:e100&#x2013;e106. doi: 10.1086/374666.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/374666</ArticleId><ArticleId IdType="pubmed">12715326</ArticleId></ArticleIdList></Reference><Reference><Citation>Tirelli U., Lleshi A., Berretta M., Spina M., Talamini R., Giacalone A. Treatment of 741 Italian patients with chronic fatigue syndrome. Eur. Rev. Med. Pharmacol. Sci. 2013;17:2847&#x2013;2852.</Citation><ArticleIdList><ArticleId IdType="pubmed">24254550</ArticleId></ArticleIdList></Reference><Reference><Citation>Oleske J. Proceedings of the CFSAC Meeting. Washington, DC, USA: May 28, 2009. Chronic Fatigue Syndrome Advisory Committee Meeting.</Citation></Reference><Reference><Citation>Speight N. Severe ME in children. Healthcare. 2020;8:211. doi: 10.3390/healthcare8030211.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/healthcare8030211</ArticleId><ArticleId IdType="pmc">PMC7551866</ArticleId><ArticleId IdType="pubmed">32674263</ArticleId></ArticleIdList></Reference><Reference><Citation>Eaton-Fitch N., Johnston S.C., Zalewski P., Staines D., Marshall-Gradisnik S. Health-related quality of life in patients with myalgic encephalomyelitis/chronic fatigue syndrome: An Australian cross-sectional study. Qual. Life Res. 2020;29:1521&#x2013;1531. doi: 10.1007/s11136-019-02411-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-019-02411-6</ArticleId><ArticleId IdType="pmc">PMC7253372</ArticleId><ArticleId IdType="pubmed">31970624</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingdon C.C., Bowman E.W., Curran H., Nacul L., Lacerda E.M. Functional status and well-being in people with myalgic encephalomyelitis/chronic fatigue syndrome compared with people with multiple sclerosis and healthy controls. Pharmaco. Econ. Open. 2018;2:381&#x2013;392. doi: 10.1007/s41669-018-0071-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s41669-018-0071-6</ArticleId><ArticleId IdType="pmc">PMC6249197</ArticleId><ArticleId IdType="pubmed">29536371</ArticleId></ArticleIdList></Reference><Reference><Citation>Roma M., Marden C.L., Flaherty M.A.K., Jasion S.E., Cranston E.M., Rowe P.C. Impaired health-related quality of life in adolescent myalgic encephalomyelitis/chronic fatigue syndrome: The impact of core symptoms. Front. Pediatr. 2019;7:26. doi: 10.3389/fped.2019.00026.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2019.00026</ArticleId><ArticleId IdType="pmc">PMC6385524</ArticleId><ArticleId IdType="pubmed">30828572</ArticleId></ArticleIdList></Reference><Reference><Citation>Nacul L.C., Lacerda E.M., Campion P., Pheby D., Drachler M.D.L., Leite J.C., Poland F., Howe A., Fayyaz S., Molokhia M. The functional status and well being of people with myalgic encephalomyelitis/chronic fatigue syndrome and their carers. BMC Public Health. 2011;11:402. doi: 10.1186/1471-2458-11-402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2458-11-402</ArticleId><ArticleId IdType="pmc">PMC3123211</ArticleId><ArticleId IdType="pubmed">21619607</ArticleId></ArticleIdList></Reference><Reference><Citation>Winger A., Kvarstein G., Wyller V.B., Ekstedt M., Sulheim D., Fagermoen E., Sm&#xe5;stuen M.C., Helseth S. Health related quality of life in adolescents with chronic fatigue syndrome: A cross-sectional study. Health Qual. Life Outcomes. 2015;13:96. doi: 10.1186/s12955-015-0288-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12955-015-0288-3</ArticleId><ArticleId IdType="pmc">PMC4490669</ArticleId><ArticleId IdType="pubmed">26138694</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy G., Underwood C., Belch J.J.F. Physical and functional impact of chronic fatigue syndrome/myalgic encephalomyelitis in childhood. Pediatrics. 2010;125:e1324&#x2013;e1330. doi: 10.1542/peds.2009-2644.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2009-2644</ArticleId><ArticleId IdType="pubmed">20478937</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson J.S., Ferrans C.E. The quality of life of persons with chronic fatigue syndrome. J. Nerv. Ment. Dis. 1997;185:359&#x2013;367. doi: 10.1097/00005053-199706000-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005053-199706000-00001</ArticleId><ArticleId IdType="pubmed">9205421</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweitzer R., Kelly B., Foran A., Terry D., Whiting J. Quality of life in chronic fatigue syndrome. Soc. Sci. Med. 1995;41:1367&#x2013;1372. doi: 10.1016/0277-9536(95)00124-P.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0277-9536(95)00124-P</ArticleId><ArticleId IdType="pubmed">8560304</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff A.L., Fagioli L.R., Doolittle T.H., Gandek B., Gleit M.A., Guerriero R.T., Kornish R.J., Ware N.C., Ware J.E., Bates D.W. Health status in patients with chronic fatigue syndrome and in general population and disease comparison groups. Am. J. Med. 1996;101:281&#x2013;290. doi: 10.1016/S0002-9343(96)00174-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9343(96)00174-X</ArticleId><ArticleId IdType="pubmed">8873490</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchwald D., Pearlman T., Umali J., Schmaling K., Katon W. Functional status in patients with chronic fatigue syndrome, other fatiguing illnesses, and healthy individuals. Am. J. Med. 1996;101:364&#x2013;370. doi: 10.1016/S0002-9343(96)00234-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9343(96)00234-3</ArticleId><ArticleId IdType="pubmed">8873506</ArticleId></ArticleIdList></Reference><Reference><Citation>Royal Brompton &amp; Harefield NHS Foundation Trust  Our Services: Immunoglobulin Therapy. 2011.  [(accessed on 8 August 2021)].  Available online:  https://www.rbht.nhs.uk/our-services/immunoglobulin-therapy.</Citation></Reference><Reference><Citation>Azizi G., Abolhassani H., Asgardoon M.H., Shaghaghi S., Negahdari B., Mohammadi J., Rezaei N., Aghamohammadi A. Managing patients with side effects and adverse events to immunoglobulin therapy. Expert Rev. Clin. Pharmacol. 2016;9:91&#x2013;102. doi: 10.1586/17512433.2016.1105131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/17512433.2016.1105131</ArticleId><ArticleId IdType="pubmed">26496172</ArticleId></ArticleIdList></Reference><Reference><Citation>US Centers for Disease Control  Treatment of ME/CFS. Updated 28 January 2021.  [(accessed on 28 June 2021)]; Available online:  https://www.cdc.gov/me-cfs/treatment/index.html.</Citation></Reference><Reference><Citation>US Centers for Disease Control  Healthcare Provider Toolkit. Page Reviewed 3 May 2021.  [(accessed on 28 June 2021)]; Available online:  https://www.cdc.gov/me-cfs/healthcare-providers/toolkit.html.</Citation></Reference><Reference><Citation>Beilby J., Torpy D., Gilles D., Burnet R., Casse R., Hundertmark J.  Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Guidelines&#x2014;Management Guidelines for General Practitioners. South Australian Department of Human Services&#x2014;Primary Health Care Branch, National Health and Medical Research Council; Adelaide, Australia: 2004.  [(accessed on 28 June 2021)].  Available online:  https://www.nhmrc.gov.au/me-cfs#download.</Citation></Reference><Reference><Citation>Accelerating Change Transformation Team. Alberta Medical Association  Towards Optimized Practice: Identification and Symptom Management of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome&#x2014;Clinical Practice Guideline. 2016.  [(accessed on 28 June 2021)].  Available online:  https://actt.albertadoctors.org/CPGs/Lists/CPGDocumentList/MECFS-CPG.pdf.</Citation></Reference><Reference><Citation>National Institute for Health and Care Excellence  Myalgic Encephalomyelitis (or Encephalopathy)/Chronic Fatigue Syndrome: Diagnosis and Management. National Guideline 206. 2021.  [(accessed on 29 October 2021)].  Available online:  https://www.nice.org.uk/guidance/ng206/resources/myalgic-encephalomyelitis-or-encephalopathychronic-fatigue-syndrome-diagnosis-and-management-pdf-66143718094021.</Citation></Reference><Reference><Citation>Smith M.E.B., Haney E., McDonagh M., Pappas M., Daeges M., Wasson N., Fu R., Nelson H.D. Treatment of myalgic encephalomyelitis/chronic fatigue syndrome: A systematic review for a National Institutes of Health Pathways to Prevention workshop. Ann. Intern. Med. 2015;162:841. doi: 10.7326/M15-0114.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M15-0114</ArticleId><ArticleId IdType="pubmed">26075755</ArticleId></ArticleIdList></Reference><Reference><Citation>Provan D., Nokes T.J.C., Agrawal S., Winer J., Wood P.  IVIg Guideline Development Group of the IVIg Expert Working Group. Clinical Guidelines for Immunoglobulin Use. 2nd ed. Department of Health; London, UK: 2008.  [(accessed on 31 July 2021)].  Available online:  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/216672/dh_130393.pdf.</Citation></Reference><Reference><Citation>Wimperis J., Lunn M., Jones A., Herriot R., Wood P., O&#x2019;Shaughnessy D., Qualie M.  Clinical Guidelines for Immunoglobulin Use. 2nd ed. Department of Health; London, UK: 2011.  [(accessed on 31 July 2021)].  Available online:  https://www.gov.uk/government/publications/clinical-guidelines-for-immunoglobulin-use-second-edition-update.</Citation></Reference><Reference><Citation>Provan D., Chapel H.M., Sewell W.A.C., O&#x2019;Shaughnessy D., on behalf of the UK Immunoglobulin Expert Working Group Prescribing intravenous immunoglobulin: Summary of department of health guidelines. BMJ. 2008;337:a1831. doi: 10.1136/bmj.a1831.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.a1831</ArticleId><ArticleId IdType="pubmed">18936060</ArticleId></ArticleIdList></Reference><Reference><Citation>Provan D., Chapel H.M., Sewell W.A.C., O&#x2019;Shaughnessy D. Department of health immunoglobulin guidelines are evidence-based and provide a framework for treatment decisions.  [(accessed on 18 August 2021)];BMJ. 2008  Available online:  https://www.bmj.com/rapid-response/2011/11/02/department-health-immunoglobulin-guidelines-are-evidence-based-and-provide.</Citation></Reference><Reference><Citation>Kindlon T. On what basis was it decided that immunoglobulin was not suitable for CFS?  [(accessed on 18 August 2021)];BMJ. 2008  Available online:  https://www.bmj.com/rapid-response/2011/11/02/what-basis-was-it-decided-immunoglobulin-was-not-suitable-cfs.</Citation></Reference><Reference><Citation>Shepherd C.B. Successful intravenous immunoglobulin treatment for parvovirus B19-associated chronic fatigue syndrome.  [(accessed on 18 August 2021)];BMJ. 2008  Available online:  https://www.bmj.com/rapid-response/2011/11/02/successful-intravenous-immunoglobulin-treatment-parvovirus-b19-associated-</Citation></Reference><Reference><Citation>Centres for Disease Control and Prevention  Information for Healthcare Providers, Clinical Care of Patients with ME/CFS.  [(accessed on 8 August 2021)]; Available online:  https://www.cdc.gov/me-cfs/healthcare-providers/clinical-care-patients-mecfs/</Citation></Reference><Reference><Citation>Darabi K., Abdel-Wahab O., Dzik W.H. Current usage of intravenous immune globulin and the rationale behind it: The Massachusetts general hospital data and a Review of the literature. Transfusion. 2006;46:741&#x2013;753. doi: 10.1111/j.1537-2995.2006.00792.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1537-2995.2006.00792.x</ArticleId><ArticleId IdType="pubmed">16686841</ArticleId></ArticleIdList></Reference><Reference><Citation>National Blood Authority  Criteria for the Clinical Use of Immunoglobulin in Australia.  [(accessed on 18 August 2021)];2018  Available online:  https://www.criteria.blood.gov.au.</Citation></Reference><Reference><Citation>Rowe K.S. Long term follow up of young people with chronic fatigue syndrome attending a pediatric outpatient service. Front. Pediatr. 2019;7:21. doi: 10.3389/fped.2019.00021.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2019.00021</ArticleId><ArticleId IdType="pmc">PMC6393360</ArticleId><ArticleId IdType="pubmed">30847333</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster A.D. Intravenous immunoglobulins. BMJ. 1991;303:375&#x2013;376. doi: 10.1136/bmj.303.6799.375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.303.6799.375</ArticleId><ArticleId IdType="pmc">PMC1670683</ArticleId><ArticleId IdType="pubmed">1912799</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepherd C. Intravenous immunoglobulin and myalgic encephalomyelitis. BMJ. 1991;303:716. doi: 10.1136/bmj.303.6804.716-c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.303.6804.716-c</ArticleId><ArticleId IdType="pmc">PMC1670935</ArticleId><ArticleId IdType="pubmed">1912925</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal A.D., VanElzakker M.B. Long COVID or post-acute sequelae of COVID-19 (PASC): An overview of biological factors that may contribute to persistent symptoms. Front. Microbiol. 2021;12:698169. doi: 10.3389/fmicb.2021.698169.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.698169</ArticleId><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanculescu D., Larsson L., Bergquist J. Hypothesis: Mechanisms that prevent recovery in prolonged ICU patients also underlie myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) Front. Med. 2021;8:628029. doi: 10.3389/fmed.2021.628029.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.628029</ArticleId><ArticleId IdType="pmc">PMC7876311</ArticleId><ArticleId IdType="pubmed">33585528</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff A.L., Lipkin W.I. Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of postacute COVID-19 syndrome. Trends Mol. Med. 2021;27:895&#x2013;906. doi: 10.1016/j.molmed.2021.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2021.06.002</ArticleId><ArticleId IdType="pmc">PMC8180841</ArticleId><ArticleId IdType="pubmed">34175230</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul B.D., Lemle M.D., Komaroff A.L., Snyder S.H. Redox imbalance links COVID-19 and myalgic encephalomyelitis/chronic fatigue syndrome. Proc. Natl. Acad. Sci. USA. 2021;118:e2024358118. doi: 10.1073/pnas.2024358118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2024358118</ArticleId><ArticleId IdType="pmc">PMC8403932</ArticleId><ArticleId IdType="pubmed">34400495</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>